SANOFI PASTEUR
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Subsidiary
- Established
- 1990-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.sanofipasteur.com
Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Infanrix®Hexa in Healthy Peruvian Infants
Phase 3
Completed
- Conditions
- Haemophilus Influenzae Type bHepatitis BPertussisDiphtheriaTetanus
- Interventions
- Biological: DTaP-HB-IPV and Haemophilus influenzae type bBiological: DTaP IPV HB PRP~T vaccine
- First Posted Date
- 2009-01-29
- Last Posted Date
- 2016-05-13
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 263
- Registration Number
- NCT00831753
Safety and Immunogenicity of the World Health Organization (WHO) Formulation of the 2004-2005 Fluzone® Vaccine
Phase 4
Completed
- Conditions
- Influenza
- First Posted Date
- 2009-01-29
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 120
- Registration Number
- NCT00831987
Study of Safety and Immunogenicity of Fluzone® in Healthy Children
Phase 4
Completed
- Conditions
- Influenza
- Interventions
- Biological: Influenza Vaccine 2004-2005 Paediatric Formulation
- First Posted Date
- 2009-01-29
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 30
- Registration Number
- NCT00831675
Safety of a Second Dose of Biken's Varicella Vaccine
Phase 4
Completed
- Conditions
- Varicella
- Interventions
- Biological: Live Attenuated Varicella Virus Vaccine
- First Posted Date
- 2009-01-28
- Last Posted Date
- 2013-06-10
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 122
- Registration Number
- NCT00830648
Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants
Phase 2
Completed
- Conditions
- PoliomyelitisDiphtheriaTetanusPertussisHaemophilus Influenzae Type b
- Interventions
- Biological: DTaP-IPV-HB-PRP~TBiological: DTaP-IPV//PRP~T combined vaccine & Recombinant hep B vaccine
- First Posted Date
- 2009-01-28
- Last Posted Date
- 2013-12-17
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 624
- Registration Number
- NCT00831311
Database Surveillance Safety Study of PENTACEL® Vaccine
Completed
- Conditions
- DiphtheriaHaemophilus InfluenzaeTetanusPertussis
- Interventions
- Biological: DTaP-IPV/HibBiological: Other DTap Vaccines
- First Posted Date
- 2008-12-08
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 62538
- Registration Number
- NCT00804284
Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™
Phase 4
Completed
- Conditions
- PolioTetanusHaemophilus InfectionPertussisDiphtheria
- Interventions
- Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis (DAPTACEL®)
- First Posted Date
- 2008-12-05
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 989
- Registration Number
- NCT00802867
Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years
Phase 2
Completed
- Conditions
- Dengue VirusDengue Hemorrhagic FeverDengue DiseasesDengue Fever
- Interventions
- Biological: CYD Dengue Vaccine Serotypes 1, 2, 3, and 4Biological: Pneumococcal polysaccharide vaccine
- First Posted Date
- 2008-11-10
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 300
- Registration Number
- NCT00788151
Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine
Phase 4
Completed
- Conditions
- MeningitisMeningococcemiaPertussisTetanusDiphtheria
- Interventions
- Biological: T dap + Meningococcal Polysaccharide Diphtheria Toxoid Conj.Biological: Tdap + Meningococcal Polysaccharide Diphtheria Toxoid Conj.Biological: Meningococcal Polysaccharide Diphtheria Toxoid Conj. + T dap
- First Posted Date
- 2008-10-22
- Last Posted Date
- 2014-02-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 1345
- Registration Number
- NCT00777257
Study of a Booster Dose of Meningococcal Diphtheria Toxoid Conjugate Vaccine in Adolescents
Phase 2
Completed
- Conditions
- MeningitisMeningococcemia
- Interventions
- Biological: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
- First Posted Date
- 2008-10-22
- Last Posted Date
- 2014-02-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 241
- Registration Number
- NCT00777790
© Copyright 2025. All Rights Reserved by MedPath